02:06 , Dec 21, 2012 |  BC Extra  |  Financial News

Nuron raises $80 million

Nuron Biotech Inc. (Exton, Pa.) raised $80 million from new investor HealthCare Royalty Partners II. The financing comprises $30 million in equity and a $50 million royalty agreement tied to future sales of Nuron products,...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

NU100: Completed Phase III enrollment

Nuron completed enrollment of 500 RRMS patients in a double-blind, placebo-controlled, European Phase III trial comparing NU100 vs. Betaferon interferon beta-1b. Nuron has exclusive, worldwide rights to NU100 from BaroFold under a 2010 deal (see...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Company News

BaroFold, Boehringer Ingelheim deal

Boehringer received non-exclusive rights to BaroFold's Pressure Enabled Manufacturing Technology (PreEMT) for the development of biologics and an option for commercialization. The technology will be installed at Boehringer's microbial facility in Vienna, Austria. PreEMT uses...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Clinical News

NU100: Phase III started

Nuron began a double-blind, placebo-controlled, international pivotal Phase III trial comparing NU100 vs. an undisclosed marketed IFN beta-1b in 500 RRMS patients. Nuron has exclusive, worldwide rights to NU100 from BaroFold under a 2010 deal...
07:00 , May 30, 2011 |  BC Week In Review  |  Company News

Nuron, PolyTherics deal

Nuron will use PolyTherics' TheraPEG site-specific PEGylation technology to develop a long-acting form of NU100 interferon beta-1b to treat relapsing-remitting multiple sclerosis (RRMS). The resulting compound will be named NU400 . Once Nuron determines a...
23:23 , May 27, 2011 |  BC Extra  |  Company News

Nuron, PolyTherics in deal for MS candidate

Nuron Biotech Inc. (Exton, Pa.) will use TheraPEG site-specific PEGylation technology from PolyTherics Ltd. (London, U.K.) to develop a long-acting version of NU100 , a recombinant interferon beta-1b in development for relapsing-remitting multiple sclerosis (MS)....
07:00 , Apr 11, 2011 |  BC Week In Review  |  Company News

Nuron Biotech, Pfizer deal

Nuron acquired Pfizer's HibTITER Haemophilus influenzae type b ( Hib ) vaccine. Nuron will have rights to market the vaccine worldwide, except in four or five "non-strategic" countries. Pfizer gained the vaccine through its 2009...
07:00 , May 24, 2010 |  BC Week In Review  |  Company News

BaroFold, Nuron Biotech deal

Newco Nuron received exclusive, worldwide rights to use BaroFold's PreEMT high pressure protein disaggregation and refolding technology to develop interferon beta products. The deal includes rights to BaroFeron interferon beta-1b, which has completed a Phase...
08:00 , Feb 2, 2009 |  BC Week In Review  |  Company News

BaroFold management update

BaroFold Inc. , Boulder, Colo.   Business: Proteomics, Autoimmune, Inflammation   Hired: J. William Freytag as president and CEO, formerly chairman and CEO of Aspreva Pharmaceuticals Corp. (now part of Galenica Ltd. )  ...
02:37 , Jan 29, 2009 |  BC Extra  |  Company News

BaroFold names Freytag CEO

Proteomics, autoimmune and inflammation company BaroFold (Boulder, Colo.) hired J. William Freytag as president and CEO. Previously, he was chairman and CEO of Aspreva , now part of Galenica (SWX:GALN)....